Shionogi Inc.

United States of America

Back to Profile

1-28 of 28 for Shionogi Inc. and 1 subsidiary Sort by
Query
Aggregations
IP Type
        Patent 20
        Trademark 8
Jurisdiction
        United States 13
        World 7
        Canada 4
        Europe 4
Owner / Subsidiary
[Owner] Shionogi Inc. 26
Victory Pharma, Inc. 2
IPC Class
A61K 9/22 - Sustained or differential release type 6
A61K 9/16 - AgglomeratesGranulatesMicrobeadlets 5
A61K 9/52 - Sustained or differential release type 5
A61K 9/14 - Particulate form, e.g. powders 4
A61K 9/54 - Sustained or differential release type containing discrete particles with coatings of different thicknesses or different materials 4
See more

1.

Solid dispersions

      
Application Number 15555839
Grant Number 10596118
Status In Force
Filing Date 2016-03-10
First Publication Date 2018-02-08
Grant Date 2020-03-24
Owner SHIONOGI, INC. (USA)
Inventor
  • Chen, Zhengming
  • Chen, Xiaoming
  • Halloran, Kevin

Abstract

An ospemifene solid dispersion for enhancing solubility and bioavailability, and methods of preparation thereof are disclosed. The solid dispersion comprises an active pharmaceutical ingredient, such as ospemifene, and a hydfophilie carrier, such as copovidone, hypromellose acetate succinate, polyvinylpyrrolidine, a polyvinylpyrrolidine/vinyl acetate co-polymer, hydroxyl propyl methylcellulose, hypromellose acetate succinate, a Eudragit® compound, hydroxypropylcellulose, a polyvinyl caprolactam-polyvinyl acetate polyethylene glycol graft co-polymer, hydroxypropyl methylcellulose phthalate, and mixtures thereof, and optionally a surfactant The ospemifene solid, dispersions can be used in methods of treating a symptom related, to menopause, such as vaginal dryness or sexual dysfunction, or in methods of treating osteoporosis.

IPC Classes  ?

  • A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
  • A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
  • A61K 9/14 - Particulate form, e.g. powders
  • A61K 47/38 - CelluloseDerivatives thereof

2.

SOLID DISPERSIONS OF OSPEMIFENE

      
Document Number 02976811
Status In Force
Filing Date 2016-03-10
Open to Public Date 2016-09-15
Grant Date 2023-06-27
Owner SHIONOGI INC. (USA)
Inventor
  • Chen, Zhengming
  • Chen, Xiaoming
  • Halloran, Kevin

Abstract

An ospemifene solid dispersion for enhancing solubility and bioavailability,, and methods of preparation thereof are disclosed. The solid dispersion comprises an active pharmaceutical ingredient, such as ospemifene, and a hydfophilie carrier, such as copovidone, hypromellose acetate succinate, polyvinylpyrrolidine, a polyvinylpyrrolidine/vinyl acetate co-polymer, hydroxy! propyl methylcellulose, hypromellose acetate succinate, a Eudragit® compound, hydroxypropylcellulose, a polyvinyl caprolactam-polyvinyl acetate polyethylene glycol graft co-polymer, hydroxypropyl methylcellulose phthalate, and mixtures thereof, and optionally a surfactant The ospemifene solid, dispersions can be used in methods of treating a symptom related, to menopause, such as vaginal dryness or sexual dysfunction, or in methods of treating osteoporosis.

IPC Classes  ?

  • A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
  • A61K 9/08 - Solutions
  • A61K 9/10 - DispersionsEmulsions
  • A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61P 15/12 - Drugs for genital or sexual disordersContraceptives for climacteric disorders

3.

SOLID DISPERSIONS

      
Application Number US2016021671
Publication Number 2016/145138
Status In Force
Filing Date 2016-03-10
Publication Date 2016-09-15
Owner SHIONOGI INC. (USA)
Inventor
  • Chen, Zhengming
  • Chen, Xiaoming
  • Halloran, Kevin

Abstract

An ospemifene solid dispersion for enhancing solubility and bioavailability,, and methods of preparation thereof are disclosed. The solid dispersion comprises an active pharmaceutical ingredient, such as ospemifene, and a hydfophilie carrier, such as copovidone, hypromellose acetate succinate, polyvinylpyrrolidine, a polyvinylpyrrolidine/vinyl acetate co-polymer, hydroxy! propyl methylcellulose, hypromellose acetate succinate, a Eudragit® compound, hydroxypropylcellulose, a polyvinyl caprolactam-polyvinyl acetate polyethylene glycol graft co-polymer, hydroxypropyl methylcellulose phthalate, and mixtures thereof, and optionally a surfactant The ospemifene solid, dispersions can be used in methods of treating a symptom related, to menopause, such as vaginal dryness or sexual dysfunction, or in methods of treating osteoporosis.

IPC Classes  ?

  • A01N 57/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds

4.

OSPHENA

      
Application Number 1161217
Status Registered
Filing Date 2013-04-17
Registration Date 2013-04-17
Owner Shionogi Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations for use in the treatment of menopausal disorders and other disorders of aging women.

5.

SENSHIO

      
Application Number 011297769
Status Registered
Filing Date 2012-10-26
Registration Date 2013-03-22
Owner Shionogi Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations for use in the treatment of menopausal disorders and other disorders of aging women.

6.

OSPHENA

      
Application Number 011251071
Status Registered
Filing Date 2012-10-09
Registration Date 2013-03-07
Owner Shionogi Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations for use in the treatment of menopausal disorders and other disorders of aging women.

7.

Miscellaneous Design

      
Application Number 011251147
Status Registered
Filing Date 2012-10-09
Registration Date 2013-03-07
Owner Shionogi Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations for use in the treatment of menopausal disorders and other disorders of aging women.

8.

OSFENA

      
Application Number 1125084
Status Registered
Filing Date 2012-06-06
Registration Date 2012-06-06
Owner Shionogi Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations for use in the treatment of menopausal disorders and other disorders of aging women.

9.

EXTENDED RELEASE FORMULATION AND METHODS OF TREATING ADRENERGIC DYSREGULATION

      
Application Number US2010061689
Publication Number 2011/079156
Status In Force
Filing Date 2010-12-22
Publication Date 2011-06-30
Owner SHIONOGI INC. (USA)
Inventor
  • Horacek, Henry Joseph
  • He, Min Michael
  • Khayrallah, Moise A.

Abstract

A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises α2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours (e.g., no more than once about every 24 hours) to a subject having a steady state plasma concentration of the α2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.

IPC Classes  ?

  • A61K 9/52 - Sustained or differential release type

10.

METHODS FOR SEDATION

      
Application Number US2010046302
Publication Number 2011/025728
Status In Force
Filing Date 2010-08-23
Publication Date 2011-03-03
Owner SHIONOGI INC. (USA)
Inventor
  • Bream, Gary
  • Butts, Stephen E.
  • Khayrallah, Moise A.

Abstract

The present invention relates to the use of compounds of the invention for producing and/or maintaining sedation in a subject in need thereof.

IPC Classes  ?

  • A01N 43/52 - 1,3-DiazolesHydrogenated 1,3-diazoles condensed with carbocyclic rings, e.g. benzimidazoles

11.

TRANSDERMAL DELIVERY OF DEXAMETHASONE AND PROMETHAZINE

      
Application Number US2008054617
Publication Number 2008/103852
Status In Force
Filing Date 2008-02-21
Publication Date 2008-08-28
Owner
  • VICTORY PHARMA, INC. (USA)
  • MEDGENEX, INCORPORATED (USA)
Inventor
  • Gonyer, Dave
  • Heck, Matthew

Abstract

Relief or prophylaxis from nausea and/or emesis are provided by transdermal compositions comprising dexamethasone and promethazine. The transdermal compositions are in the form of transdermal solutions and/or suspensions, such as lotions, pastes, gels, ointments or transdermal patches.

IPC Classes  ?

  • A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
  • A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
  • A61K 9/70 - Web, sheet or filament bases

12.

COMBINED ADMINISTRATION OF BENZONATATE AND GUAIFENESIN

      
Application Number US2008051198
Publication Number 2008/089260
Status In Force
Filing Date 2008-01-16
Publication Date 2008-07-24
Owner VICTORY PHARMA, INC. (USA)
Inventor
  • Heck, Thomas
  • Cvijanovich, Michael

Abstract

Pharmaceutical compositions are provided containing a combination of benzonatate and guaifenesin, or pharmaceutically acceptable salts thereof. Methods of using compositions comprising benzonatate and guaifenesin, or pharmaceutically acceptable salts thereof, provide relief from cough, pulmonary congestion or both. The compositions and methods provide relief to opiate-sensitive individuals, in particular, as well as to infants and other pediatric patients.

IPC Classes  ?

  • A61K 9/22 - Sustained or differential release type

13.

Modified release amoxicillin products

      
Application Number 11633315
Grant Number 08778924
Status In Force
Filing Date 2006-12-04
First Publication Date 2008-06-05
Grant Date 2014-07-15
Owner Shionogi Inc. (USA)
Inventor
  • Flanner, Henry H.
  • Tolle-Sander, Sanna
  • Treacy, Donald
  • Burnside, Beth A.
  • Clausen, Susan P.

Abstract

An amoxicillin product comprising: at least one modified release component(s), wherein the at least one modified release component(s) comprises at least amoxicillin and a pharmaceutically acceptable carrier; and wherein when administered to a patient or subject in the fed state said amoxicillin product exhibits a pharmacokinetic profile for amoxicillin in the plasma characterized as follows: (1) the ratio of the portion of the AUC as measured from 2 hours post-administration to 5 hours post-administration to the portion of the AUC as measured from administration to 2 hours post-administration is at least 2.0:1; and (2) the ratio of the portion of the AUC as measured from 5 hours post-administration to 12 hours post-administration to the portion of the AUC as measured from administration to 2 hours post-administration is at least 1.1:1.

IPC Classes  ?

  • A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems

14.

Pharmaceutical compositions and methods for improved bacterial eradication

      
Application Number 11800574
Grant Number 08299052
Status In Force
Filing Date 2007-05-07
First Publication Date 2008-02-28
Grant Date 2012-10-30
Owner Shionogi Inc. (USA)
Inventor
  • Flanner, Henry H.
  • Guttendorf, Robert
  • Treacy, Donald
  • Clausen, Susan P.
  • Burnside, Beth A.

Abstract

A process for treating a bacterial infection with an antibiotic, comprising: administering to a patient with a bacterial infection a product that includes a modified release dosage form containing an antibiotic, said product being administered once-a-day in a dosage and for a number of days that provides a Total T>MIC sufficient to achieve at least the minimum amount of bacterial eradication for treatment of said bacterial infection.

IPC Classes  ?

  • A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • A61K 9/22 - Sustained or differential release type

15.

Compositions and methods for improved efficacy of penicillin-type antibiotics

      
Application Number 11636291
Grant Number 08357394
Status In Force
Filing Date 2006-12-08
First Publication Date 2007-06-14
Grant Date 2013-01-22
Owner Shionogi Inc. (USA)
Inventor
  • Flanner, Henry H.
  • Guttendorf, Robert J.
  • Clausen, Susan P.
  • Treacy, Donald
  • Burnside, Beth A.

Abstract

90, while providing a total dosage of the penicillin-type antibiotic for a 24-hour dosing interval.

IPC Classes  ?

16.

Tablet for pulsed delivery

      
Application Number 11173929
Grant Number 08715727
Status In Force
Filing Date 2005-07-01
First Publication Date 2006-01-05
Grant Date 2014-05-06
Owner Shionogi Inc. (USA)
Inventor
  • Cao, Bruce
  • Wassink, Sandra E.
  • Treacy, Jr., Donald J.
  • Burnside, Beth A.
  • Rowlings, Colin E.
  • Bonck, John A.

Abstract

A pharmaceutical tablet comprising an immediate release portion containing an active ingredient and a delayed release portion, wherein the delayed release portion comprises an enteric-coated layer and within the enteric-coated layer there is at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated mini-tablet dosage forms containing an active ingredient, is disclosed.

IPC Classes  ?

  • A61K 9/22 - Sustained or differential release type

17.

Antibiotic product, use and formulation thereof

      
Application Number 10940265
Grant Number 08460710
Status In Force
Filing Date 2004-09-14
First Publication Date 2005-03-17
Grant Date 2013-06-11
Owner Shionogi, Inc. (USA)
Inventor
  • Burnside, Beth A.
  • Flanner, Henry H.
  • Rowlings, Colin

Abstract

max at different times.

IPC Classes  ?

  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 9/22 - Sustained or differential release type
  • A61K 9/26 - Discrete particles in supporting matrix
  • A61K 9/52 - Sustained or differential release type
  • A61K 9/54 - Sustained or differential release type containing discrete particles with coatings of different thicknesses or different materials

18.

Antibiotic product, use and formulation thereof

      
Application Number 10922412
Grant Number 08246996
Status In Force
Filing Date 2004-08-20
First Publication Date 2005-03-03
Grant Date 2012-08-21
Owner Shionogi Inc. (USA)
Inventor
  • Burnside, Beth A.
  • Flanner, Henry H.
  • Rowlings, Colin

Abstract

max at different times.

IPC Classes  ?

  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • A61K 9/22 - Sustained or differential release type
  • A61K 9/26 - Discrete particles in supporting matrix
  • A61K 9/52 - Sustained or differential release type
  • A61K 9/54 - Sustained or differential release type containing discrete particles with coatings of different thicknesses or different materials

19.

Robust pellet

      
Application Number 10915912
Grant Number 08758820
Status In Force
Filing Date 2004-08-11
First Publication Date 2005-02-17
Grant Date 2014-06-24
Owner Shionogi Inc. (USA)
Inventor
  • Cao, Bruce X.
  • Burnside, Beth A.
  • Wassink, Sandra E.
  • Baker, Matt R.

Abstract

Compositions and methods for making robust pellets that contain a high percentage, by weight, of active drug agent, and which also contain additional components that enhance the absorption and solubility of the active drug agent within the gastrointestinal tract (GI tract) without diminishing the robust nature of the pellet, are disclosed.

IPC Classes  ?

  • A61K 9/14 - Particulate form, e.g. powders
  • A61K 9/50 - Microcapsules
  • A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
  • C07D 499/00 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penemsSuch ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

20.

ANTIBIOTIC PRODUCT, USE AND FORMULATION THEREOF

      
Document Number 02533178
Status In Force
Filing Date 2004-07-20
Open to Public Date 2005-02-03
Grant Date 2014-03-11
Owner SHIONOGI INC. (USA)
Inventor
  • Burnside, Beth A.
  • Flanner, Henry H.
  • Rowlings, Colin

Abstract

An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a delayed release dosage form, and a sustained release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.

IPC Classes  ?

  • A61K 9/14 - Particulate form, e.g. powders
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 9/24 - Layered or laminated unitary dosage forms
  • A61K 9/52 - Sustained or differential release type
  • A61K 9/54 - Sustained or differential release type containing discrete particles with coatings of different thicknesses or different materials

21.

ANTIBIOTIC PRODUCT, USE AND FORMULATION THEREOF

      
Document Number 02533292
Status In Force
Filing Date 2004-07-20
Open to Public Date 2005-02-03
Grant Date 2013-12-31
Owner SHIONOGI INC. (USA)
Inventor
  • Burnside, Beth A.
  • Flanner, Henry H.
  • Rowlings, Colin

Abstract

An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, a sustained release dosage form, and a delayed release dosage form, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form

22.

ANTIBIOTIC PRODUCT, USE AND FORMULATION THEREOF

      
Document Number 02533358
Status In Force
Filing Date 2004-07-20
Open to Public Date 2005-02-03
Grant Date 2014-03-11
Owner SHIONOGI INC. (USA)
Inventor
  • Burnside, Beth A.
  • Flanner, Henry H.
  • Rowlings, Colin

Abstract

An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more sustained release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.

IPC Classes  ?

  • A61K 9/14 - Particulate form, e.g. powders
  • A61K 9/20 - Pills, lozenges or tablets
  • A61K 9/24 - Layered or laminated unitary dosage forms
  • A61K 9/52 - Sustained or differential release type
  • A61K 9/54 - Sustained or differential release type containing discrete particles with coatings of different thicknesses or different materials

23.

Antibiotic product, use and formulation thereof

      
Application Number 10894787
Grant Number 08425936
Status In Force
Filing Date 2004-07-20
First Publication Date 2005-01-27
Grant Date 2013-04-23
Owner Shionogi Inc. (USA)
Inventor
  • Burnside, Beth A.
  • Flanner, Henry H.
  • Rowlings, Colin

Abstract

max at different times.

IPC Classes  ?

24.

Antibiotic product, use and formulation thereof

      
Application Number 10894994
Grant Number 08313776
Status In Force
Filing Date 2004-07-20
First Publication Date 2005-01-27
Grant Date 2012-11-20
Owner Shionogi Inc. (USA)
Inventor
  • Burnside, Beth A.
  • Flanner, Henry H.
  • Rowlings, Colin

Abstract

max at different times.

IPC Classes  ?

  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets

25.

Antibiotic product, use and formulation thereof

      
Application Number 10894786
Grant Number 08313775
Status In Force
Filing Date 2004-07-20
First Publication Date 2005-01-27
Grant Date 2012-11-20
Owner Shionogi Inc. (USA)
Inventor
  • Burnside, Beth A.
  • Flanner, Henry H.
  • Rowlings, Colin

Abstract

max at different times.

IPC Classes  ?

  • A61K 9/16 - AgglomeratesGranulatesMicrobeadlets

26.

ALTOPREV

      
Application Number 003875986
Status Registered
Filing Date 2004-07-09
Registration Date 2005-08-12
Owner Shionogi Inc. (USA)
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Oral pharmaceutical preparations containing a cholesterol lowering drug.

27.

XODOL

      
Serial Number 78256758
Status Registered
Filing Date 2003-06-02
Registration Date 2005-04-19
Owner SHIONOGI INC. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

Pharmaceutical preparation for the treatment of pain, inflammation, and fever

28.

FORTAMET

      
Serial Number 78115656
Status Registered
Filing Date 2002-03-18
Registration Date 2005-03-01
Owner SHIONOGI INC. ()
NICE Classes  ? 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

ANTIDIABETIC PHARMACEUTICAL PREPARATIONS, NAMELY, PHARMACEUTICALS CONTAINING A BIGUANIDE ACTIVE INGREDIENT, NAMELY, METFORMIN